- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07556159
Eine Studie zur Bewertung von Krankheitsmerkmalen und Ergebnissen bei Teilnehmern mit Asthma in der routinemäßigen klinischen Praxis (AIRITY)
Eine hybride Querschnitts- und prospektive Studie zur Beurteilung von Patientencharakteristika, Krankheitslast, Krankheitskontrolle, Phänotypen, Endotypen und Ergebnissen im realen Umfeld bei Patienten mit Asthma
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Trial Transparency email recommended-Toll free for US & Canada
- Telefonnummer: 6 800-633-1610
- E-Mail: Contact-US@sanofi.com
Studienorte
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), Deutschland, 85039
- Rekrutierung
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Deutschland, 53119
- Rekrutierung
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, Deutschland, 09337
- Rekrutierung
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, Deutschland, 24837
- Rekrutierung
- Investigational Site Number: 276502
-
-
-
-
Brittany Region
-
Brest, Brittany Region, Frankreich, 29200
- Rekrutierung
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, Frankreich, 34400
- Rekrutierung
- Investigational Site Number: 250612
-
Toulouse, Occitanie, Frankreich, 31059
- Rekrutierung
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, Frankreich, 85000
- Rekrutierung
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Frankreich, 95100
- Rekrutierung
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, Frankreich, 94010
- Rekrutierung
- Investigational Site Number: 250609
-
-
-
-
-
Niigata, Japan
- Rekrutierung
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, Japan, 802-0083
- Rekrutierung
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, Japan, 761-8073
- Rekrutierung
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, Japan, 849-8501
- Rekrutierung
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Rekrutierung
- Investigational Site Number: 392710
-
tabashi City, Tokyo, Japan, 173-8610
- Rekrutierung
- Investigational Site Number: 392709
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3R 1W7
- Rekrutierung
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, Kanada, N8X 2G1
- Rekrutierung
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, Kanada, G8T7A1
- Rekrutierung
- Investigational Site Number: 124204
-
-
-
-
-
Madrid, Spanien, 28034
- Rekrutierung
- Investigational Site Number: 724408
-
-
-
-
Alabama
-
Bessemer, Alabama, Vereinigte Staaten, 35022
- Rekrutierung
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, Vereinigte Staaten, 85224
- Zurückgezogen
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, Vereinigte Staaten, 85206
- Aktiv, nicht rekrutierend
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, Vereinigte Staaten, 85254
- Rekrutierung
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, Vereinigte Staaten, 85351
- Aktiv, nicht rekrutierend
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, Vereinigte Staaten, 91107
- Aktiv, nicht rekrutierend
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, Vereinigte Staaten, 90623
- Aktiv, nicht rekrutierend
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, Vereinigte Staaten, 90017
- Aktiv, nicht rekrutierend
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, Vereinigte Staaten, 92663
- Aktiv, nicht rekrutierend
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, Vereinigte Staaten, 91101
- Aktiv, nicht rekrutierend
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, Vereinigte Staaten, 91356
- Zurückgezogen
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, Vereinigte Staaten, 94598
- Aktiv, nicht rekrutierend
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, Vereinigte Staaten, 32701
- Aktiv, nicht rekrutierend
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, Vereinigte Staaten, 33431
- Aktiv, nicht rekrutierend
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, Vereinigte Staaten, 33511
- Aktiv, nicht rekrutierend
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, Vereinigte Staaten, 33467
- Aktiv, nicht rekrutierend
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, Vereinigte Staaten, 33126
- Aktiv, nicht rekrutierend
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, Vereinigte Staaten, 33126
- Aktiv, nicht rekrutierend
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, Vereinigte Staaten, 33130
- Aktiv, nicht rekrutierend
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, Vereinigte Staaten, 33142
- Aktiv, nicht rekrutierend
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, Vereinigte Staaten, 33145
- Aktiv, nicht rekrutierend
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, Vereinigte Staaten, 33155
- Aktiv, nicht rekrutierend
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, Vereinigte Staaten, 33173
- Aktiv, nicht rekrutierend
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, Vereinigte Staaten, 33174
- Aktiv, nicht rekrutierend
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, Vereinigte Staaten, 33186
- Aktiv, nicht rekrutierend
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, Vereinigte Staaten, 33014
- Aktiv, nicht rekrutierend
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, Vereinigte Staaten, 33014
- Aktiv, nicht rekrutierend
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, Vereinigte Staaten, 33014
- Aktiv, nicht rekrutierend
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, Vereinigte Staaten, 33016
- Aktiv, nicht rekrutierend
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, Vereinigte Staaten, 33169
- Aktiv, nicht rekrutierend
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, Vereinigte Staaten, 33406
- Aktiv, nicht rekrutierend
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, Vereinigte Staaten, 33317
- Aktiv, nicht rekrutierend
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, Vereinigte Staaten, 34986
- Aktiv, nicht rekrutierend
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Aktiv, nicht rekrutierend
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, Vereinigte Staaten, 33613
- Aktiv, nicht rekrutierend
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, Vereinigte Staaten, 33409
- Aktiv, nicht rekrutierend
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, Vereinigte Staaten, 31904
- Aktiv, nicht rekrutierend
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60616
- Aktiv, nicht rekrutierend
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40509
- Aktiv, nicht rekrutierend
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, Vereinigte Staaten, 21045
- Rekrutierung
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, Vereinigte Staaten, 20854
- Aktiv, nicht rekrutierend
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, Vereinigte Staaten, 59808
- Aktiv, nicht rekrutierend
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, Vereinigte Staaten, 68046
- Aktiv, nicht rekrutierend
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, Vereinigte Staaten, 08080
- Aktiv, nicht rekrutierend
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, Vereinigte Staaten, 13045
- Aktiv, nicht rekrutierend
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, Vereinigte Staaten, 12553
- Aktiv, nicht rekrutierend
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, Vereinigte Staaten, 10029
- Aktiv, nicht rekrutierend
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801
- Aktiv, nicht rekrutierend
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, Vereinigte Staaten, 28054-7489
- Aktiv, nicht rekrutierend
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, Vereinigte Staaten, 27834-2849
- Rekrutierung
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, Vereinigte Staaten, 45801
- Aktiv, nicht rekrutierend
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, Vereinigte Staaten, 43617
- Aktiv, nicht rekrutierend
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15241
- Aktiv, nicht rekrutierend
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, Vereinigte Staaten, 29732
- Aktiv, nicht rekrutierend
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, Vereinigte Staaten, 30909
- Aktiv, nicht rekrutierend
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75235
- Aktiv, nicht rekrutierend
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, Vereinigte Staaten, 79902
- Aktiv, nicht rekrutierend
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, Vereinigte Staaten, 77090
- Aktiv, nicht rekrutierend
- Lumi Research - Site Number: 840156
-
Houston, Texas, Vereinigte Staaten, 77099
- Aktiv, nicht rekrutierend
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, Vereinigte Staaten, 76054
- Aktiv, nicht rekrutierend
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, Vereinigte Staaten, 77081
- Aktiv, nicht rekrutierend
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, Vereinigte Staaten, 98225
- Aktiv, nicht rekrutierend
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
Beschreibung
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Zeitfenster: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Zeitfenster: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Zeitfenster: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Zeitfenster: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Zeitfenster: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Zeitfenster: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Zeitfenster: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Teil 1: Anzahl der Teilnehmer, charakterisiert nach ihren demografischen und klinischen Merkmalen
Zeitfenster: Teil 1: Ab 12 Monaten vor der Studienteilnahme
|
Teil 1: Ab 12 Monaten vor der Studienteilnahme
|
|
|
Teil 1: Anzahl der Teilnehmer nach Krankheitslast, Gesundheitszustand und Behandlungserfahrungen
Zeitfenster: Teil 1: Von 12 Monaten vor Studieneinschreibung
|
Teil 1: Von 12 Monaten vor Studieneinschreibung
|
|
|
Teil 1: Anzahl der Teilnehmer, charakterisiert nach Medikamentengebrauch
Zeitfenster: Teil 1: Ab 12 Monaten vor Studieneinschreibung
|
Teil 1: Ab 12 Monaten vor Studieneinschreibung
|
|
|
Teil 1: Anzahl der Teilnehmer, charakterisiert nach ihrem Lebensstil und Umwelteinflüssen
Zeitfenster: Teil 1: Von 12 Monaten vor Studieneinschluss
|
Teil 1: Von 12 Monaten vor Studieneinschluss
|
|
|
Teil 1: Anzahl der Teilnehmer charakterisiert durch die Einnahme inhalativer und systemischer Kortikosteroide
Zeitfenster: Teil 1: Von 12 Monaten vor Studieneinschreibung
|
Teil 1: Von 12 Monaten vor Studieneinschreibung
|
|
|
Teil 1: Anzahl der Teilnehmer, charakterisiert nach Inanspruchnahme von Gesundheitsressourcen (HCRU)
Zeitfenster: Teil 1: Ab 12 Monate vor Studieneinschluss
|
Teil 1: Ab 12 Monate vor Studieneinschluss
|
|
|
Teil 2: Deskriptive Charakterisierung einschließlich soziodemografischer Daten, Krankheitsmerkmalen und Behandlungsanamnese.
Zeitfenster: Teil 2: Zu Beginn
|
Teil 2: Zu Beginn
|
|
|
Teil 2: Jahresexazerbationsraten in Woche 52 und 104
Zeitfenster: Teil 2: In Woche 52 und 104
|
Teil 2: In Woche 52 und 104
|
|
|
Teil 2: Anzahl der Teilnehmer, die auf Änderungen der eingeatmeten und systemischen Kortikosteroidbelastung analysiert wurden
Zeitfenster: Teil 2: Vom Ausgangswert bis zur Woche 104
|
Teil 2: Vom Ausgangswert bis zur Woche 104
|
|
|
Teil 2: Veränderungen des Biomarkerspiegels
Zeitfenster: Teil 2: In den Wochen 52 und 104
|
Teil 2: In den Wochen 52 und 104
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Zeitfenster: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Zeitfenster: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Zeitfenster: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Zeitfenster: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Zeitfenster: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Zeitfenster: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Zeitfenster: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Zeitfenster: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Zeitfenster: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Zeitfenster: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
Zeitfenster: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PIR21191
- 2025-524916-13-00 (Ctis)
- U1111-1336-5183 (Registrierungskennung: ICTRP)
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .